Compulsory Licenses: A Tool to Improve Global Access to the HPV Vaccine?
In: American Journal of Law & Medicine, Jg. 35 (2009), S. 323
Online
academicJournal
I. INTRODUCTION Cancer is the third leading cause of female deaths worldwide and cervical cancer is the fifth deadliest form of cancer in women. 1 Every year about half a million women are diagnosed with the disease, and more than a quarter of a million die from it. 2 But the burden of cervical cancer is not shared equally among women from all corners of the globe. More than 85 percent of new cervical cancer cases occur in lower- and middle-income countries. 3 Notably, cervical cancer is the leading cause of cancer deaths among women in the African and South East Asia regions, while it is the tenth most common cause of cancer deaths among women in high-income regions and countries like the United States, Canada, Japan, and the countries of the European Union. 4 The extremely high morbidity from cervical cancer among women in the developing world is largely attributed to the absence of regular and effective pre-cancer screening and treatment services. 5 The good news is that two recently developed vaccines appear, so far, to be highly effective at preventing infection with the two strains of the human papillomavirus (HPV) that cause 70 percent of cervical cancer. 6 The bad news is that these vaccines, GlaxoSmithKline's (GSK) Cervarix(R) and Merck's Gardasil(R), are much more expensive on average than other vaccines, and are too expensive to facilitate widespread global vaccination against HPV. The three-dose series of Gardasil costs $ 360 in the United States ...
Titel: |
Compulsory Licenses: A Tool to Improve Global Access to the HPV Vaccine?
|
---|---|
Autor/in / Beteiligte Person: | Maybardule, Peter |
Link: | |
Zeitschrift: | American Journal of Law & Medicine, Jg. 35 (2009), S. 323 |
Veröffentlichung: | 2009 |
Medientyp: | academicJournal |
Schlagwort: |
|
Sonstiges: |
|